IL277577A - Antibody-based methods of detecting and treating alzheimer's disease - Google Patents

Antibody-based methods of detecting and treating alzheimer's disease

Info

Publication number
IL277577A
IL277577A IL277577A IL27757720A IL277577A IL 277577 A IL277577 A IL 277577A IL 277577 A IL277577 A IL 277577A IL 27757720 A IL27757720 A IL 27757720A IL 277577 A IL277577 A IL 277577A
Authority
IL
Israel
Prior art keywords
antibody
disease
detecting
based methods
treating alzheimer
Prior art date
Application number
IL277577A
Other languages
Hebrew (he)
Original Assignee
Axon Neuroscience Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience Se filed Critical Axon Neuroscience Se
Publication of IL277577A publication Critical patent/IL277577A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL277577A 2018-03-28 2020-09-24 Antibody-based methods of detecting and treating alzheimer's disease IL277577A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862649208P 2018-03-28 2018-03-28
US201862664662P 2018-04-30 2018-04-30
US201862703299P 2018-07-25 2018-07-25
PCT/IB2019/000358 WO2019186276A2 (en) 2018-03-28 2019-03-27 Antibody-based methods of detecting and treating alzheimer's disease

Publications (1)

Publication Number Publication Date
IL277577A true IL277577A (en) 2020-11-30

Family

ID=66999856

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277577A IL277577A (en) 2018-03-28 2020-09-24 Antibody-based methods of detecting and treating alzheimer's disease

Country Status (12)

Country Link
EP (1) EP3774887A2 (en)
JP (1) JP2021520777A (en)
KR (1) KR20200144551A (en)
CN (1) CN112236452A (en)
AU (1) AU2019244481A1 (en)
BR (1) BR112020018868A2 (en)
CA (1) CA3095443A1 (en)
IL (1) IL277577A (en)
MX (1) MX2020009991A (en)
RU (1) RU2020135052A (en)
SG (1) SG11202008098TA (en)
WO (1) WO2019186276A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
PT3452507T (en) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Tau immunotherapy
KR102784294B1 (en) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 Tau recognition antibody
CN111201030B (en) 2017-07-25 2024-11-01 真和制药有限公司 Treating cancer by blocking the interaction between TIM-3 and its ligands
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
JP7630834B2 (en) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド Tau recognition antibody
JP2022547513A (en) 2019-09-09 2022-11-14 アクソン ニューロサイエンス エスエー Biomarkers and treatments for Alzheimer's disease and mild cognitive impairment
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHODS OF TREATING INFLAMMATORY DISEASES BY BLOCKADE OF GALECTIN-3
CN117043183A (en) * 2020-12-16 2023-11-10 沃雅戈治疗公司 TAU binding compounds
MX2023008317A (en) * 2021-02-19 2023-07-24 Eisai R&D Man Co Ltd Anti-pt217 tau antibody.
AU2022246660A1 (en) * 2021-03-31 2023-10-12 Washington University Csf phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies
CN117003863A (en) * 2022-04-28 2023-11-07 厦门大学 Antibodies against p-tau 217 and their uses
CN114778856B (en) * 2022-05-30 2023-03-17 苏州宇测生物科技有限公司 Phosphorylated tau protein detection kit
CN115078736B (en) * 2022-06-24 2025-03-25 佛山市观迪医疗器械有限公司 A homogeneous immunoassay kit for Alzheimer's disease
CN119836437A (en) * 2022-08-19 2025-04-15 舒泰神(加州)生物科技有限公司 Antibodies specifically recognizing apoptosis 1 ligand 1 and uses thereof
CN117624351B (en) * 2023-11-24 2024-07-05 无锡傲锐东源生物科技有限公司 Anti-human phosphorylated tau181 rabbit monoclonal antibody and application thereof
CN120118184A (en) * 2023-12-08 2025-06-10 深圳湾实验室 Specific binding proteins targeting Tau and their applications
WO2025160022A1 (en) * 2024-01-26 2025-07-31 Beckman Coulter, Inc. Detecting phosphorylated tau (p-tau) 217 using chemiluminescent dioxetane compounds
CN119334929B (en) * 2024-11-19 2026-02-24 中元汇吉生物技术股份有限公司 Method for improving detection sensitivity of phosphorylated tau protein and kit thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE191853T1 (en) 1992-07-27 2000-05-15 Us Health TARGETING LIPOSOMES FOR THE BLOOD-BRAIN BARRIER
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CU22615A1 (en) 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
ES2434840T3 (en) 1995-07-27 2013-12-17 Genentech, Inc. Formulation of stable isotonic lyophilized protein
DK0871490T3 (en) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Branched hydrazone linkers
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
DE10121982B4 (en) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanoparticles of protein with coupled apolipoprotein E to overcome the blood-brain barrier and process for their preparation
US20060167227A1 (en) 2002-07-12 2006-07-27 Axon Neuroscience Forschungs-Und Entwicklungs Gmbh Truncated tau proteins
JP4995423B2 (en) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Artificial low density lipoprotein carrier for transporting substances across the blood-brain barrier
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
US8093018B2 (en) * 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
JP5599454B2 (en) * 2009-08-06 2014-10-01 イムナス・ファーマ株式会社 Antibody specifically binding to Aβ oligomer and use thereof
ME03008B (en) * 2011-09-19 2018-10-20 Axon Neuroscience Se PROTEIN AND DIAGNOSIS THERAPY DIAGNOSIS THAT BROUGHT TAU IN ALCNAIMER DISEASE
MX350311B (en) * 2011-12-20 2017-09-01 Janssen Biotech Inc Anti-phf-tau antibodies and their uses.
US8853505B2 (en) * 2012-02-27 2014-10-07 Syngenta Participations Ag Variety corn line AA2205
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN107428820B (en) 2014-11-19 2022-03-22 阿克松神经系统科学公司 Humanized tau antibodies in alzheimer's disease
CA3013254A1 (en) * 2016-02-05 2017-08-10 Jiangsu Hengrui Medicine Co., Ltd. Thrombin antibody, antigen-binding fragment and pharmaceutical use thereof

Also Published As

Publication number Publication date
AU2019244481A1 (en) 2020-10-01
WO2019186276A2 (en) 2019-10-03
CA3095443A1 (en) 2019-10-03
WO2019186276A8 (en) 2020-10-15
EP3774887A2 (en) 2021-02-17
MX2020009991A (en) 2020-10-14
WO2019186276A3 (en) 2020-02-27
BR112020018868A2 (en) 2021-01-26
JP2021520777A (en) 2021-08-26
SG11202008098TA (en) 2020-10-29
KR20200144551A (en) 2020-12-29
CN112236452A (en) 2021-01-15
RU2020135052A (en) 2022-04-29

Similar Documents

Publication Publication Date Title
IL277577A (en) Antibody-based methods of detecting and treating alzheimer's disease
PT3873604T (en) Methods for treating alzheimer's disease
IL280315A (en) Methods for treating and preventing Alzheimer's disease
IL254030B (en) Use of pridopidine to improve cognitive function and for treating alzheimer's disease
IL288894A (en) Methods for evaluation and treatment of alzheimer's disease and applications thereof
IL276896A (en) Methods of treating crohn's disease with anti-il23 specific antibody
IL263433A (en) Methods for treating Alzheimer's disease
EP3347486A4 (en) REDUCTION OF C99 FRAGMENT OF APP LOCALIZED ON ER-MAM MEMBRANE AND METHODS OF TREATING ALZHEIMER'S DISEASE
DK3643321T3 (en) PLASMINOGEN FOR USE IN THE TREATMENT OF PARKINSON'S AND ALZHEIMER'S DISEASE
EP3558340A4 (en) Methods of using gm6 in diagnosing and treating alzheimer's disease
EP3773500A4 (en) Compositions and methods of detecting and treating alzheimer's disease
EP3493818A4 (en) METHODS FOR DETECTION AND TREATMENT OF A PT346 PDK1 EXPRESSING TUMOR
EP3407858A4 (en) METHOD FOR TREATING THE DISGARNED APPEARANCE OF HAIR
ES3064246T3 (en) Compounds for use in methods for treating alzheimer's disease
EP3398614A4 (en) AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE
IL265911A (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease
IL248935A0 (en) Diagnostic test and treatment/prevention of alzheimer's disease
PL3137097T3 (en) Treatment and prevention of alzheimer's disease (ad)
EP3672619A4 (en) MATERIALS AND METHODS FOR CANCER ASSESSMENT AND TREATMENT
IL274536A (en) Methods for prognosis or treatment of parkinson's disease
IL271637B (en) Agent for preventing and/or treating alzheimer’s disease
PL3137094T3 (en) Treatment and prevention of alzheimer's disease (ad)
IL265656A (en) Compositions and methods for treating alzheimer's disease and parkinson's disease
ZA202001588B (en) Method of treating alzheimer's disease
HK40038500A (en) Antibody-based methods of detecting and treating alzheimer's disease